Lasa Supergenerics Ltd

The transcript from the provided pages of the Lasa Supergenerics Limited earnings call does not explicitly mention details about the current or expected order book or pending orders. However, relevant points include: - The company is focusing on growth with a targeted year-on-year increase of 22%-25%. - There is optimism about improved profits in the second half due to backward integration (Unit-IV and upcoming Unit-V). - Export contributes about 40% of total sales. - The company is gradually moving towards formulations as a forward integration but has not yet entered this space. - Growth depends on acquisitions and new business opportunities but no specific order book figures or backlog orders are discussed. Therefore, no explicit information about specific order book size or pending orders is available in the provided transcript.

- Capex is ongoing and essential for the company’s operations; without it, the company cannot run (Page 11). - The CAPEX turnover ratio is approximately 1:1 for greenfield expansions and about 3.5 times for brownfield expansions (additional equipment) (Page 11). - Unit IV (formerly Unit V) has been commissioned and production has started; trial runs are finishing, and commercial production will commence soon (Pages 13-14). - Incremental turnover from new units, like Unit V, is expected primarily from next financial year FY19 onwards (Page 16). - The company plans to continue capitalizing CWIP (Capital Work in Progress) year on year as new assets become operational (Page 14). - Forward integration into formulations is planned but timelines are uncertain, with priority currently on debt reduction before major expansion (Page 13). - Omkar Herlekar has lent Rs. 14 crores as loans to the company, indicating internal financial support for operations (Page 11). Overall, ongoing and future capex is planned with focus on expanding production capacity and integrating forward into formulations, while managing debt carefully.